Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Takeda Pharmaceuticals new drug application for Actoplus Met for the treatment of type 2 diabetes. The product combines two widely used diabetes medications in a single tablet.
Subscribe to our email newsletter
Actoplus met combines the diabetes drugs Actos and metformin. Actos directly targets insulin resistance, a condition where the body does not efficiently use the insulin it produces, and metformin acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels.
This is the second Takeda product approved in the US this summer, following the approval of Rozerem on July 22, 2005.
“To reach target blood glucose levels, many people with type 2 diabetes will have to take a combination of therapies. In fact, within three years of being prescribed their first medication, approximately 50% of patients will need to add additional therapies to manage their condition,” said Dr Ralph DeFronzo, professor of medicine at the University of Texas Health Science Center.
“Actoplus met may help patients reduce the number of pills they take each day, and offers a new and convenient treatment option,” added Dr DeFronzo.
According to the American Diabetes Association, diabetes affects more than 18 million people, and type 2 diabetes is the most common form of the disease.